OBJECTIVE: Race specific assessment of pregnancy is important as it allows the identification of women who are at an increased risk of certain pathology and enhanced monitoring. This study explored the association between angiogenic markers (soluble fms-like tyrosine kinase-1 [sFlt1] and placental growth factor [PlGF] ) in African American (AA) and white women who were normotensive and those with hypertensive disorders of pregnancy (HDP). STUDY DESIGN: Normotensive women and those HDP were enrolled upon admission and blood samples were collected within 96 hours prior to delivery. Angiogenic markers were measured on an automated platform. Data was collected from medical records. For analysis patients were stratified into having a HDP or not. RESULTS: Data was collected on a total of 608 women, of which 477 (78%) were black and 131 (22%) were white. Age, infant birthweight and the prevalence of nulliparity was significantly higher in white women as compared to AA women (Table 1) . On the contrary, body mass index was significantly higher in AA women as compared to white women (median BMI 28.1 vs 25.8; p¼0.01). Other interventions including antepartum medication administration was similar between groups.
When comparing angiogenic profiles, the median PlGF was significantly higher (p¼0.001) and the median sFlt1/PlGF was lower (p¼0.03) among AA women as compared to white women, regardless of hypertensive status. No difference was seen between sFlt1 and racial group (p¼0.80).
Consistent with previous studies by our group and others, abnormal angiogenic factors were observed among patients with a HDP. When stratifying by hypertensive status (within or without a HDP), the relationship between PlGF and race persisted. Unexpectedly, this was most pronounced among normotensive women, as AA women experienced a higher median PlGF of 245 pg/mL (interquartile range 133-495) as compared to a median PlGF of 151 pg/mL (IQR: 75-250) in white women (Table 2) . CONCLUSION: This study demonstrates a significant association between PlGF and race. Additional evaluation of the role of angiogenic markers during assessment for HDP in AA women as compared to white women and disease severity is needed. Factors other than angiogenic factors needs to be evaluated to explain higher prevalence of HDP in AA women.
Poster Session III OBJECTIVE: Hypertensive disorders of pregnancy (HDP) confer significant maternal risks postpartum including risks of seizure, stroke and higher rates of postpartum readmission. Following delivery, women with blood pressure elevations are treated primarily with labetalol or nifedipine but it is unknown if one agent is more effective for blood pressure control following hospital discharge. We sought to compare rates of postpartum readmission and adverse maternal outcomes based on discharge on labetalol versus nifedipine. STUDY DESIGN: We identified women 15 to 44 years of age with a delivery admission in the Truven Health MarketScanÒ Commercial Claims and Encounters Database (2011-14) who were discharged on labetalol or nifedipine based on having a prescription filled either during the delivery admission or within 4 days of discharge. Two groups of HDP were examined: 1) gestational hypertension/preeclampsia without severe features and 2) preeclampsia with severe features/eclampsia. We calculated the rates of readmission for eclampsia, stroke or any reason up to 6 weeks postpartum by medication and indication for use and the odds of readmission for each medication within HDP groups. RESULTS: Among our cohort of 980,666 deliveries, 6.4% experienced gestational hypertension/preeclampsia without severe features (mild disease) and 2.5% severe preeclampsia/eclampsia. 28.5% of women with mild disease and 39.3% with severe preeclampsia/eclampsia were discharged on either medication. The overall readmission rate in the cohort was 1.1% (n¼11,016). Rates of readmission increased with increasing severity of HDP: mild disease 2.2% (p<0.001), and severe preeclampsia/eclampsia 3.3% (p<0.001). Across all HDP groups, readmission rates tended to be higher for women discharged on labetalol (4.3%-5.2%) (Table) . Specifically, when compared to women discharged without medications, women with mild disease discharged on labetalol were more likely to be readmitted with eclampsia (OR 4.39, ) and women with severe preeclampsia were more likely to be readmitted for any reason (OR 1.51, 95% CI 1.29-1.77). CONCLUSION: Women with HDP represent a high-risk group for postpartum readmission. Compared to nifedipine, discharge on labetalol is associated with increased rates of readmission for severe manifestations of HDP, eclampsia and stroke.
